Literature DB >> 32265610

Intravenous Immunoglobulin Infusion Reactions in Kawasaki Disease Patients Who Undergo Sedation.

Elizabeth Nguyen, Daniel Hershey, Gale Romanowski, Adriana Tremoulet.   

Abstract

OBJECTIVES: Although IVIG infusions are usually well tolerated, reactions can include hypotension, chills, and, rarely, anaphylactic reactions. Risk of adverse reactions correlates with dose and rate of IVIG infusion. An echocardiogram is the preferred imaging modality to detect coronary artery changes in acute Kawasaki disease (KD), but the quality of the study can be compromised if a child moves much during the imaging procedure. Thus, sedation is often required for children younger than 3 years of age. There is concern regarding coadministration of IVIG and sedatives. Therefore, the purpose of this analysis is to determine when the majority of IVIG infusion reactions occur to help find the optimal time to safely perform a sedated echocardiogram in patients with KD.
METHODS: This is a retrospective, single-center analysis of patients with KD administered IVIG at Rady Children's Hospital San Diego from November 1, 2013, to October 31, 2016.
RESULTS: Of the 260 subjects in this study, 34 (13%) had an IVIG infusion reaction consisting of either chills or hypotension. There were no anaphylactic reactions. All infusion reactions occurred within 4 hours of starting IVIG. No hypotension reactions occurred after 4 hours. All subjects were able to complete their IVIG infusion without any further complications.
CONCLUSIONS: Given that the maximum IVIG infusion rate is reached at 1.5 hours per our hospital's policy and that the overwhelming majority of infusion reactions occurred within the first 4 hours, we found it is safe to coadminister IVIG with sedation 4 hours after initiation of IVIG infusion. Copyright Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2020.

Entities:  

Keywords:  Kawasaki disease; adverse drug reaction; echocardiogram; infusion reactions; intravenous immunoglobulin; pediatrics

Year:  2020        PMID: 32265610      PMCID: PMC7134588          DOI: 10.5863/1551-6776-25.3.251

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  9 in total

Review 1.  Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence.

Authors:  Patrick Cherin; Isabelle Marie; Mauricette Michallet; Eric Pelus; Jacques Dantal; Jean-Charles Crave; Jean-Christophe Delain; Jean-François Viallard
Journal:  Autoimmun Rev       Date:  2015-09-16       Impact factor: 9.754

Review 2.  Intravenous immunoglobulin: adverse effects and safe administration.

Authors:  Hedi Orbach; Uriel Katz; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.

Authors:  Danielli C Bichuetti-Silva; Fernanda P Furlan; Fernanda A Nobre; Camila T M Pereira; Tessa R T Gonçalves; Mariana Gouveia-Pereira; Rafael Rota; Lusinete Tavares; Juliana T L Mazzucchelli; Beatriz T Costa-Carvalho
Journal:  Int Immunopharmacol       Date:  2014-09-22       Impact factor: 4.932

4.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

5.  Predictors of coronary artery visualization in Kawasaki disease.

Authors:  Renee Margossian; Minmin Lu; L LuAnn Minich; Timothy J Bradley; Meryl S Cohen; Jennifer S Li; Beth F Printz; Girish S Shirali; Lynn A Sleeper; Jane W Newburger; Steven D Colan
Journal:  J Am Soc Echocardiogr       Date:  2011-01       Impact factor: 5.251

Review 6.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.

Authors:  Brian W McCrindle; Anne H Rowley; Jane W Newburger; Jane C Burns; Anne F Bolger; Michael Gewitz; Annette L Baker; Mary Anne Jackson; Masato Takahashi; Pinak B Shah; Tohru Kobayashi; Mei-Hwan Wu; Tsutomu T Saji; Elfriede Pahl
Journal:  Circulation       Date:  2017-03-29       Impact factor: 29.690

7.  Infliximab treatment of pancreatitis complicating acute kawasaki disease.

Authors:  Susan G Jimenez-Fernandez; Adriana H Tremoulet
Journal:  Pediatr Infect Dis J       Date:  2012-10       Impact factor: 2.129

8.  Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.

Authors:  Adriana H Tremoulet; Sonia Jain; Preeti Jaggi; Susan Jimenez-Fernandez; Joan M Pancheri; Xiaoying Sun; John T Kanegaye; John P Kovalchin; Beth F Printz; Octavio Ramilo; Jane C Burns
Journal:  Lancet       Date:  2014-02-24       Impact factor: 79.321

9.  Specificity of regulatory T cells that modulate vascular inflammation.

Authors:  Alessandra Franco; Ranim Touma; Yali Song; Chisato Shimizu; Adriana H Tremoulet; John T Kanegaye; Jane C Burns
Journal:  Autoimmunity       Date:  2014-02-04       Impact factor: 2.815

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.